- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07937852
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)
A Multicenter, Single Arm, Open-label, Extension, Roll-over Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis
The primary purpose of this study is to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Study Contact Backup
- Name: Reference Study ID Number: CN45787 https://forpatients.roche.com/ No attachments to email below.
- Phone Number: 888-662-6728
- Email: global-roche-genentech-trials@gene.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Previous eligibility and participation in the open-label extension (OLE) phase of an eligible Roche-sponsored parent study, where the participant is receiving fenebrutinib as an investigational medicinal product (IMP)
- Minimum of 24 weeks exposure to open-label fenebrutinib in parent study
- Ability and willingness to comply with all aspects of the protocol including completion of procedures, interviews, questionnaires, assessments for the duration of the study
Exclusion Criteria:
- Concurrent participation in any clinical trial (other than the parent study). Participants who withdrew from fenebrutinib treatment in their respective parent study should also be excluded
- Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
- Chronic liver disease unless considered stable for >6 months
- Acute liver disease
- Cirrhosis (Child-Pugh Class A, B, or C)
- Gilbert's syndrome
- Aspartate aminotransferase (ALT) or alanine aminotransferase (AST) > 1.5 × upper limit of normal (ULN)
- Total bilirubin greater than 1.5 × ULN
- A "yes" on any item of the Suicidal Behavior section of the Columbia-Suicide Severity Rating Scale (C-SSRS) or significant risk of a suicide, in the investigator's judgment
Note: Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Fenebrutinib
Participants receiving fenebrutinib in OLE of their parent study may be eligible for enrollment in this extension study. Participants will continue fenebrutinib treatment at the dosage and route of administration received at the time of rollover from the parent study. |
Fenebrutinib will be administered as per the schedule specified in the protocol.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants With Adverse Events (AEs)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Expanded Disability Status Scale (EDSS) Score Over Time
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in 9-hole Peg Test (9-HPT) Over Time
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Timed 25-foot Walk Test (T25FWT) Over Time
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of 24-week Confirmed Disability Progression (CDP24)
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of Modified cCDP24
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of 24-week Confirmed Disability Improvement (CDI24)
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Number of New or Enlarging T2 Magnetic Resonance Imaging (MRI) Lesions
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Number of T1 Hypointense MRI Lesions
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Volume of T2 Lesions
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Volume of T1 Hypointense Lesions
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Brain Volume
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Annualized Relapse Rate (ARR) (for Relapsing Multiple Sclerosis [RMS] Participants Only)
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Patient-reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a) Over Time
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Multiple Sclerosis Impact Scale - 29-item (MSIS-29), Version 2 Physical Scale Over Time
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in MSIS-29 Psychological Scale Over Time
Time Frame: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CN45787
- 2026-526037-26-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.